{
    "nctId": "NCT01779206",
    "briefTitle": "ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer",
    "officialTitle": "Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 4936,
    "primaryOutcomeMeasure": "Identification of a responder sub-population with intermediate and high risk, which due to therapy has outcome comparable to HR+/RS\u226411",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients, age at diagnosis 18 years and above (consider patients at 70 years and above for ADAPT Elderly)\n* Histologically confirmed unilateral primary invasive carcinoma of the breast\n* Clinical T1 - T4 (except inflammatory breast cancer)\n* All clinical N (cN)\n* No clinical evidence for distant metastasis (M0)\n* Known HR status and HER2 status (local pathology)\n* Tumor block available for central pathology review\n* Performance Status ECOG \\<= 1 or KI \\>= 80%\n* Negative pregnancy test (urine or serum) within 7 days prior to start of induction treatment in premenopausal patients\n* Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements\n* The patient must be accessible for treatment and follow-up\n\nAdditional Inclusion criteria for patients receiving chemotherapy:\n\n* Laboratory requirements for patients receiving neoadjuvant chemotherapy (within 14 days prior to induction treatment):\n\n  * Leucocytes \\>= 3.5 x 10\\^9/L\n  * Platelets \\>= 100 x 10\\^9/L\n  * Hemoglobin \\>= 10 g/dL\n  * Total bilirubin \\<= 1 x ULN\n  * ASAT (SGOT) and ALAT (SGPT) \\<= 2.5 x UNL\n  * Creatinine \\<= 175 \u00b5mol/L (2 mg/dl)\n* LVEF within normal limits of each institution measured by echocardiography and normal ECG (within 42 days prior to induction treatment)\n\nExclusion Criteria:\n\n* Known hypersensitivity reaction to the compounds or incorporated substances\n* Prior malignancy with a disease-free survival of \\< 10 years, except curatively treated basalioma of the skin or pTis of the cervix uteri\n* Non-operable breast cancer including inflammatory breast cancer\n* Previous or concurrent treatment with cytotoxic agents for any reason after consultation with the sponsor\n* Concurrent treatment with other experimental drugs. Participation in another interventional clinical trial with or without any investigational not marketed drug within 30 days prior to study entry\n* Male breast cancer\n* Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment\n* Breast feeding woman\n* Sequential breast cancer\n* Reasons indicating risk of poor compliance\n* Patients not able to consent\n\nAdditional Exclusion Criteria for patients receiving chemotherapy:\n\n* Known polyneuropathy \u2265 grade 2\n* Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including acute cystitis and ischuria and chronic kidney disease\n* Uncompensated cardiac function\n* Inadequate organ function including:\n\n  * Leucocytes \\< 3.5 x 10\\^9/l\n  * Platelets \\< 100 x 10\\^9/l\n  * Bilirubin above normal limits\n  * Alkaline phosphatase \\>= 5 x UNL\n  * ASAT and/or ALAT associated with AP \\> 2.5 x UNL",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}